Chris Wilkinson, head of sales for Healthcare for Siemens Financial Services in the UK, looks at the value of new-generation digitalised technology within the pharmaceutical industry.
New-generation digitalised technology (also known as Industry 4.0) is enabling manufacturers across a range of sectors to improve performance through increased manufacturing productivity, more accurate planning and forecasting, enhanced competitive capabilities and greater financial sustainability. In the pharmaceutical sector, for example, digitalisation and data analytics can reduce the high levels of downtime typically experienced by pharmaceutical plants.